TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) just unveiled an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced an update regarding its final cash dividend for the year ended December 31, 2024. The dividend, approved by shareholders, is set at RMB 2.5 per 10 shares, with a payment date scheduled for July 7, 2025. The announcement details the withholding tax rates applicable to different categories of shareholders, highlighting the company’s compliance with the Enterprise Income Tax Law of the People’s Republic of China. This update reflects the company’s commitment to maintaining transparency with its stakeholders and adhering to regulatory requirements.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$3.88 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of heparin and related products. The company is known for its contributions to the global supply of heparin, a critical anticoagulant used in medical treatments.
Average Trading Volume: 3,012,416
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.02B
For a thorough assessment of 9989 stock, go to TipRanks’ Stock Analysis page.